Clinical Trials Browser

INDUSTRY × Interventional × veltuzumab × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01101581 2021-08-18

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00285428 2021-08-17

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Phase 1/2 Completed

82 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT00546793 2021-08-16

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Phase 1/2 Completed

32 enrolled

LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, B-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT01390545 2016-04-13

VELVET

Phase 2 Terminated

300 enrolled

Arthritis, Rheumatoid

Clinical Trials

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

VELVET